MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Reversible, Cell-Permeable Proteasome Inhibitor

Executive Summary: MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a boronic acid peptide that selectively and reversibly inhibits proteasome chymotryptic activity at an IC50 of 122 nM, with high cell permeability and solubility in DMSO and ethanol (APExBIO). It induces cell cycle arrest and apoptosis by modulating key regulators such as p21, p27, and caspases under standard cell culture conditions. MG-262 has been validated for research on osteoclast differentiation, cancer, inflammatory, and neurodegenerative models, but requires fresh preparation due to solution instability. The product supports mechanistic studies of the ubiquitin-proteasome system, with evidence from both in vitro and in vivo models (Thorne et al., 2023).

Biological Rationale

The ubiquitin-proteasome system (UPS) controls regulated protein degradation in eukaryotic cells. Proteasome activity is essential for cell cycle progression, DNA replication, and apoptosis. Inhibitors of the proteasome, such as MG-262, enable functional dissection of these processes. The UPS modulates levels of cell cycle regulators (e.g., p21, p27), apoptosis inhibitors (BIRC2, BIRC3), and transcription factors such as NF-κB, which are implicated in cancer, inflammation, and neurodegenerative diseases (Thorne et al., 2023). Dysregulation of proteasomal degradation can lead to accumulation of misfolded or damaged proteins, contributing to pathogenesis in a variety of disease models.

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a boronic acid peptide that selectively and reversibly inhibits the chymotryptic-like activity of the 26S proteasome. The boronic acid moiety forms a covalent, but reversible, bond with the active site threonine of the proteasome catalytic subunit. This interaction blocks proteolytic cleavage of targeted proteins and prevents downstream degradation. MG-262 displays high cell permeability, allowing intracellular inhibition of proteasome activity in cellular and tissue models. Its IC50 for proteasome inhibition is 122 nM under standard in vitro conditions (APExBIO). The chymotryptic activity is essential for degradation of regulatory proteins involved in cell proliferation and survival, making MG-262 a critical tool for pathway interrogation.

Evidence & Benchmarks

• MG-262 exhibits an IC50 of 122 nM for proteasome chymotryptic activity inhibition in biochemical assays at 37°C in buffer (APExBIO, product page).
• It is soluble at ≥24.57 mg/mL in DMSO and ≥96.4 mg/mL in ethanol, but insoluble in water (APExBIO, product page).
• MG-262 induces cell cycle arrest in nasal mucosa and polyp fibroblasts by upregulating p21 and p27 expression and inhibiting retinoblastoma phosphorylation (Kim et al., 2016, DOI).
• It triggers apoptosis via mitochondrial membrane potential loss, caspase-3 activation, and PARP cleavage in cultured cells (Kim et al., 2016, DOI).
• MG-262 inhibits osteoclast differentiation in a dose-dependent manner in mouse bone marrow cultures (Xiong et al., 2014, DOI).
• Following intravenous administration, MG-262 reduces proteasome activity in multiple organs in vivo (Xiong et al., 2014, DOI).
• NF-κB pathway regulation, including BIRC2/BIRC3 expression, is experimentally linked to proteasome function in pulmonary epithelial cells (Thorne et al., 2023, DOI).

Applications, Limits & Misconceptions

MG-262 is widely used in:

• Cancer research: Interrogating proteasome-mediated degradation of tumor suppressors and oncogenes.
• Inflammatory disease models: Modulating NF-κB signaling and cytokine responses.
• Neurodegenerative disease models: Studying protein aggregation and cell death mechanisms.
• Osteoclast differentiation: Inhibiting bone resorption pathways.
• Cell cycle arrest and apoptosis research: Dissecting checkpoints and programmed cell death.

Compared to other proteasome inhibitors, MG-262 offers reversible inhibition and high cell permeability. For a comparison with irreversible proteasome inhibitors, see our article on Bortezomib (MG-262 provides reversible action and distinct solubility properties). For insights into cell cycle control under proteasome inhibition, review our MG-132 overview (MG-262 exhibits greater selectivity and reversibility than MG-132). This article updates our summary of the proteasome inhibitor toolkit by detailing the specific workflow advantages of MG-262.

Common Pitfalls or Misconceptions

• MG-262 is not suitable for aqueous (water-based) stock solutions: It is insoluble in water and should be dissolved in DMSO or ethanol.
• MG-262 solutions are unstable: Solutions should be prepared immediately before use; storage at -20°C is recommended for the dry compound only (APExBIO).
• Reversibility does not mean lack of off-target effects: At high concentrations, MG-262 can inhibit other proteases.
• Not all cell types respond identically: Sensitivity to proteasome inhibition may vary between cell lines and primary cultures.
• MG-262 does not directly degrade proteins: It blocks proteasomal degradation, leading to accumulation of target proteins.

Workflow Integration & Parameters

• Solubility: Dissolve MG-262 at ≥24.57 mg/mL in DMSO or ≥96.4 mg/mL in ethanol; avoid aqueous buffers.
• Storage: Store powder at -20°C, protected from moisture and light.
• Preparation: Prepare working solutions immediately before use to minimize degradation; discard unused solution.
• Assay recommendation: For proteasome inhibition assays, use MG-262 at concentrations spanning 10 nM to 1 μM, depending on cell type and endpoint.
• Controls: Include DMSO- or ethanol-only controls to account for solvent effects.

For ordering and technical details, consult the MG-262 (Z-Leu-Leu-Leu-B(OH)2) A8179 data sheet from APExBIO.

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a validated, reversible, and cell-permeable proteasome inhibitor with robust in vitro and in vivo utility. Its selectivity and potency, combined with practical handling parameters, make it a preferred tool in studies of cancer, inflammatory, and neurodegenerative disease mechanisms. Researchers should heed solubility and stability constraints and ensure protocol alignment for reproducible results. Future directions include optimizing delivery for in vivo systems and deeper investigation into cell-type specific responses to proteasome inhibition.